Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Undiagnosed Diseases Network, |
RCV001255605 | SCV001432131 | uncertain significance | CDK19-related disorder | 2019-11-25 | criteria provided, single submitter | clinical testing | This individual has been published in PMID: 32330417. |
| Ambry Genetics | RCV002560185 | SCV003544628 | pathogenic | Inborn genetic diseases | 2021-10-08 | criteria provided, single submitter | clinical testing | The c.586A>G (p.T196A) alteration is located in exon 6 (coding exon 6) of the CDK19 gene. This alteration results from an A to G substitution at nucleotide position 586, causing the threonine (T) at amino acid position 196 to be replaced by an alanine (A). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported de novo in two unrelated patients with a neurodevelopmental disorder with features including developmental delay, intellectual disability, epilepsy, hypotonia, autistic features, and abnormal brain MRI (Chung, 2020). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). Functional studies using flies have shown that loss of Cdk8, the fly homolog of CDK19, causes larval lethality, which is suppressed by expression of human CDK19 reference cDNA. In contrast, the CDK19 p.T196A variant fails to rescue the loss of Cdk8 and behaves as a null allele (Chung, 2020). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. |
| OMIM | RCV001195089 | SCV001365385 | pathogenic | Developmental and epileptic encephalopathy, 87 | 2020-10-21 | no assertion criteria provided | literature only |